GSK plc (NYSE:GSK) Shares Purchased by Natixis Advisors L.P.

Natixis Advisors L.P. boosted its position in shares of GSK plc (NYSE:GSK) by 10.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 325,676 shares of the pharmaceutical company’s stock after acquiring an additional 31,566 shares during the period. Natixis Advisors L.P.’s holdings in GSK were worth $12,069,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the company. Raymond James Financial Services Advisors Inc. raised its stake in GSK by 17.6% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 307,057 shares of the pharmaceutical company’s stock valued at $11,131,000 after buying an additional 45,890 shares in the last quarter. Stratos Wealth Partners LTD. lifted its stake in GSK by 13.4% during the third quarter. Stratos Wealth Partners LTD. now owns 21,458 shares of the pharmaceutical company’s stock worth $778,000 after purchasing an additional 2,536 shares during the last quarter. Lindbrook Capital LLC boosted its holdings in GSK by 50.2% in the third quarter. Lindbrook Capital LLC now owns 2,953 shares of the pharmaceutical company’s stock valued at $107,000 after purchasing an additional 987 shares in the last quarter. Verdence Capital Advisors LLC boosted its holdings in GSK by 7.0% in the third quarter. Verdence Capital Advisors LLC now owns 7,237 shares of the pharmaceutical company’s stock valued at $262,000 after purchasing an additional 473 shares in the last quarter. Finally, Advisor Partners II LLC increased its stake in GSK by 20.6% in the third quarter. Advisor Partners II LLC now owns 27,956 shares of the pharmaceutical company’s stock valued at $1,013,000 after purchasing an additional 4,766 shares during the last quarter. 15.74% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on GSK shares. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. Citigroup raised GSK from a “neutral” rating to a “buy” rating in a report on Tuesday, February 13th. Finally, Morgan Stanley assumed coverage on GSK in a report on Tuesday, January 23rd. They issued an “equal weight” rating for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, GSK has an average rating of “Moderate Buy”.

GSK Stock Up 1.6 %

GSK stock opened at $44.15 on Wednesday. GSK plc has a 12 month low of $33.33 and a 12 month high of $44.33. The company has a debt-to-equity ratio of 1.15, a current ratio of 0.87 and a quick ratio of 0.58. The company has a market cap of $91.50 billion, a price-to-earnings ratio of 16.00, a price-to-earnings-growth ratio of 1.85 and a beta of 0.65. The company has a fifty day moving average price of $41.93 and a 200 day moving average price of $39.30.

GSK Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Friday, May 17th will be given a dividend of $0.3762 per share. This is a positive change from GSK’s previous quarterly dividend of $0.36. This represents a $1.50 annualized dividend and a dividend yield of 3.41%. The ex-dividend date is Thursday, May 16th. GSK’s payout ratio is presently 57.61%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.